ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug ...

The final trades of the day with the Fast Money traders.

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

Teva Pharmaceuticals (TEVA) and Alvotech (ALVO) announced the availability of SELARSDI injection in the U.S., a biosimilar to Stelara for the ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

New research shows that 46% of generic drugs from the European Union (EU) critical list of medicines are supplied by just one ...

Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...

A diversified supply of critical generic medicines from multiple manufacturers is required to ensure that healthcare systems can meet the needs of their patients. The research shows that for most ...

Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...